Biostable vaccines

Half of all vaccines delivered, for example, are wasted due to problems with the ‘cold chain’.

porter

In very hot areas like parts of sub-Saharan Africa, the lack of medical facilities means many people, particularly children, are not vaccinated.

cold store

For more information about the problems associated with delivering vaccines see the World Health Organisation's website.

www.who.int

 

Further Information
Applications

Vaccines, traditionally, need to be refrigerated from the moment of manufacture until just hours before being administered. At higher temperatures, or if they freeze, they lose their potency.

Therefore, wherever and whenever they are needed, a 'cold chain' has to be established to keep them at the correct temperature until used.

The World Health Organisation (WHO) has estimated this cost at $200m - $300m per year - enough to vaccinate an additional 10 million children worldwide.

Cambridge Biostability's technology effectively eliminates the need for the cold chain by producing vaccines which are undamaged by freezing and are stable at high temperatures for years. This allows vaccines to reach areas that were previously impossible to get to, allowing those who live in the world's most remote locations to receive the medical supplies they so desperately need. The Global Alliance for Vaccines and Immunisation New Technology Working Group (NTWG) has reviewed the impact of new technologies on future vaccination programs.

Their report:

http://www.gavialliance.org/resources/12_board_techrep.pdf

shows that adoption of our stable liquid vaccine technology could save between $200 and $342 Million per year.

Finding the way to a fulfilling life of learning and experience thru Biotechnology


e. [email protected]